Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure

Human Gene Therapy

Volumn 11, Issue 13, 2000, Pages 1891-1900

  Rizzuto, G ^a   Cappelletti, M ^a   Mennuni, C ^a   Wiznerowicz, M ^a   DeMartis, A ^a   Maione, D ^a   Ciliberto, G ^a   La Monica, N ^a   Fattori, E ^a  

^a IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ERYTHROPOIETIN; PLASMID DNA; VIRUS VECTOR;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENE THERAPY; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; PROTEIN SYNTHESIS; QUADRICEPS FEMORIS MUSCLE; RABBIT; RAT;

ANEMIA; ANIMALS; CYTOMEGALOVIRUS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOCRIT; INJECTIONS; KIDNEY FAILURE, CHRONIC; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; NEPHRECTOMY; PLASMIDS; PROMOTER REGIONS (GENETICS); RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TRANSDUCTION, GENETIC;

EID: 0034283880     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050129503     Document Type: Article

References (49)

1. Gene transfer into muscle by electroporation in vivo
2. Factors which affect erythropoiesis in partially nephrectomised and sham-operated rats
3. Adenovirus vectors for gene delivery
4. Secreted human placental alkaline phosphatase as a reporter gene for in vivo gene transfer
5. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts
6. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
7. Experimental renal insufficiency produced by partial nephrectomy
8. Immune responses to adenovirus and adeno-associated virus in humans
9. Modulating the immune response to genetic immunization
10. Keratinocytes as a target for gene therapy. Sustained production of erythropoietin in mice by human keratinocytes transduced with an adeno-associated virus vector
11. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus
12. Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial
13. Recombinant human erythropoietin in anaemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
14. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure
15. Cancer gene therapy using plasmid DNA: Purification of DNA for human clinical trials
16. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease
17. Direct gene transfer into non-human primate myofibers in vivo
18. Effect of purified recombinant human erythropoietin on anaemia in rats with experimental renal failure
19. Mechanism of hypoalbuminemia in the 7/8 nephrectomised rat with chronic renal failure
20. Chronic renal failure
21. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
22. Hormonal modulation of a gene injected into rat heart in vivo
23. Safe and effective regulation of hematocrit by gene gun administration of an erythropoietin-encoding plasmid
24. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA transfer
25. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector
26. Erythropoietic effects of tri-iodothyronine on the anaemia of renal failure in rats: Comparative studies with testosterone and erythropoietin
27. Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation
28. Electropermeabilization of skeletal muscle enhances gene transfer in vivo
29. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle
30. High-efficiency gene transfer into skeletal muscle mediated by electric pulses
31. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors
32. Gene therapy for long-term expression of erythropoietin in rats
33. Cytokines and costimulatory molecules as genetic adjuvants
34. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure
35. Regulation of gene expression in vivo following transduction by two separate rAAV vectors
36. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation
37. Murine erythropoietin gene: Cloning, expression and human gene homology
38. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice
39. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector
40. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus
41. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
42. Effect of erythropoietin on anaemia of peritoneally dialysed anephric rats
43. Gene transfer in regenerating muscle
44. Evidence that inhibition of erythropoiesis is important in the anaemia of chronic renal failure
45. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: Application to melanoma vaccine development
46. Long term persistence of plasmid DNA and foreign gene expression in mouse muscle
47. Metabolic intermediates and inorganic ions
48. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmid expressing cytokines
49. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer